Anti-SARS-CoV-2 antibody response
There was no significant difference between the treatment groups in SARS-CoV-2-specific anti-RBD IgG concentration at four weeks after the second vaccination dose (Anti-SARS-CoV-2 antibody and T-lymphocyte response. After adjusting for total lymphocyte count (Seroconversion increased from 19% in the FCM group and 17% in the placebo group (